Enanta Pharmaceuticals Stock Performance
| ENTA Stock | USD 13.31 -0.04 -0.30% |
Risk-Adjusted Performance
Soft
Weak | Strong |
Enanta Pharmaceuticals currently ranks below 2% of comparable global equities and portfolios when recent risk-adjusted returns are measured across a 90-day horizon. In practice, the ranking separates absolute gains from efficient gains. Enanta Pharmaceuticals is delivering weak return efficiency relative to its risk profile. Current price dislocation suggests continued short-term downside pressure for investors. Learn More
Actual Historical Performance (%)
One Day Return -0.30 | Five Day Return -4.66 | Year To Date Return -15.60 | Ten Year Return -57.56 | All Time Return -22.53 |
1 | Equities Analysts Issue Forecasts for ENTA Q 2 Earnings | 02/12/2026 |
2 | ENT Allergy Associates Announces Plans to Integrate Epic Across Its Network Elevating the Patient Experience and Care Coordination | 02/25/2026 |
3 | Enanta Pharmaceuticals Share Price Passes Above 200-Day Moving Average - Heres Why - Market Beat | 03/06/2026 |
4 | Acquisition by Carter Bruce L A of 20000 shares of Enanta Pharmaceuticals at 14.17 subject to Rule 16 b-3 | 03/11/2026 |
5 | Enanta director receives 20,000-share stock option grant - Stock Titan | 03/13/2026 |
6 | Enanta Pharmaceuticals Stock Crosses Below Two Hundred Day Moving Average - Whats Next - Market Beat | 03/24/2026 |
7 | Enanta Biotech Momentum Builds Across Nasdaq Index | 03/27/2026 |
8 | Disposition of 5142 shares by Jay Luly of Enanta Pharmaceuticals at 8.06 subject to Rule 16 b-3 | 04/06/2026 |
9 | Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Viru... | 04/07/2026 |
10 | ENTA Stock Price, Quote Chart ENANTA PHARMACEUTICALS INC - Chart Mill | 04/10/2026 |
11 | Disposition of 2283 shares by Tara Kieffer of Enanta Pharmaceuticals at 8.06 subject to Rule 16 b-3 | 04/15/2026 |
12 | Insider Trading | 04/16/2026 |
Performance Related Modules
Earnings links to analyst estimate history and revisions, Ownership shows shareholder mix, Profitability focuses on margin and return ratios, Liquidity covers cash-flow strength and short-term funding capacity, and Fundamentals groups the broader financial ratio set.
Relative Risk vs. Return Landscape
If you had invested $ 1,292 in Enanta Pharmaceuticals on January 26, 2026 and sold it today you would have earned a total of $ 39.00 from holding Enanta Pharmaceuticals or generated 3.02% return on investment over 90 days. Enanta Pharmaceuticals is currently generating a 0.092% daily expected return and carries 3.0231% risk (volatility on return distribution) over a 90-day horizon. In relative terms, Enanta exhibits above-average volatility, exceeding roughly 73% of comparable stocks, and ENTA has trailed 99% of traded instruments in return over the 90-day horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
A fundamental principle of stock forecasting is that prices tend to revert toward historical averages. This pattern serves as a foundation for forecasting, even though some stocks exhibit persistent deviations. One possible explanation is that these stocks carry additional risk requiring compensation through extra returns.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 13.31 | 90 days | 13.31 | about 59.74 |
According to our probability model, the chance of Enanta Pharmaceuticals moving above the current price in 90 days from now is about 59.74 . Based on past return behavior, the distribution of outcomes has been weighted above current levels over this period. (This distribution highlights the price region that has carried the highest probability weight for Enanta Stock over a 90-day horizon).
Enanta Pharmaceuticals Price Density |
| Price |
Predictive Modules for Enanta Pharmaceuticals
Forecasting Enanta Pharmaceuticals involves applying various models to estimate future stock price behavior. Despite uncertainty, systematic forecasting provides investors with structured context for evaluating Enanta Pharmaceuticals. Comparing results across methods can improve accuracy, even in unpredictable stock markets.The concept of mean reversion suggests that Enanta Pharmaceuticals' price will eventually return toward its long-run average. Positions sized too aggressively against the trend often suffer sustained losses before reversion occurs in Enanta Pharmaceuticals. The mean reversion framework for Enanta Pharmaceuticals is built on the premise that markets are not perfectly efficient.
Primary Risk Indicators
Market volatility over the last 10-20 years has created both risk and opportunity across stock markets including Enanta Pharmaceuticals. The pattern of corrections and recoveries in Enanta Pharmaceuticals mirrors the broader stock market experience. Implementing a hedging strategy and tracking Enanta Pharmaceuticals' volatility limits the impact of adverse moves.α | Alpha over Dow Jones | 0.12 | |
β | Beta against Dow Jones | 1.67 | |
σ | Overall volatility | 0.73 | |
Ir | Information ratio | 0.04 |
Investor Alerts and Insights
Real-time alerts for Enanta Pharmaceuticals track important stock developments as they happen. Notifications for Enanta Pharmaceuticals highlight significant technical and fundamental shifts that may signal emerging risks. Each alert is generated from real-time data feeds monitoring Enanta Pharmaceuticals price action and volume.| Enanta Pharmaceuticals had very high historical volatility over the last 90 days | |
| Enanta Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| ENTA reported previous year's revenue of 65.32 M. Net Loss for the year was -81.89 M with profit before overhead, payroll, taxes, and interest of 66.98 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash as of latest reporting with -19.27 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22. | |
| Enanta Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 2283 shares by Tara Kieffer of Enanta Pharmaceuticals at 8.06 subject to Rule 16 b-3 |
Price Density Drivers
Understanding the forces behind Enanta Pharmaceuticals' price movements requires examining buyer and seller positioning dynamics. These indicators capture key forces that influence Enanta Pharmaceuticals' near-term price behavior and volatility. Enanta Pharmaceuticals' indicators related to price density are summarized below for reference.
| Common Stock Shares Outstanding | 21.3 M | |
| Cash And Short Term Investments | 188.9 M |
Enanta Pharmaceuticals Fundamentals Growth
Investors assess Enanta Stock by examining Enanta Pharmaceuticals' underlying financial health and growth trajectory. Core fundamentals including revenue growth, earnings quality, and debt management directly influence Enanta Stock. These fundamentals can have a significant impact on Enanta Stock performance across market cycles.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | -1.07 | ||||
| Operating Margin | -0.6 | ||||
| Current Valuation | 258.05 M | ||||
| Shares Outstanding | 29.02 M | ||||
| Price To Earnings | 366.13 X | ||||
| Price To Book | 3.06 X | ||||
| Price To Sales | 5.77 X | ||||
| Revenue | 65.32 M | ||||
| Gross Profit | 66.98 M | ||||
| EBITDA | -70.78 M | ||||
| Net Income | -81.89 M | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 201.06 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 4.36 X | ||||
| Cash Flow From Operations | -19.27 M | ||||
| Earnings Per Share | -3.21 X | ||||
| Market Capitalization | 386.25 M | ||||
| Total Asset | 280.73 M | ||||
| Retained Earnings | -404.93 M | ||||
| Working Capital | 155.78 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
Performance Metrics & Calculation Methodology
Return quality for Enanta Pharmaceuticals evaluates how consistent and repeatable performance has been across periods. High return quality implies that outcomes are not dominated by a small number of extreme observations. Enanta Pharmaceuticals shows ROE of -60.01%, ROA of -13.47% (TTM) vs -32.0% (last reported).
Enanta Pharmaceuticals data is compiled from periodic company reporting and market reference feeds and standardized for comparability. Return and risk statistics are calculated from historical price series.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board